Episode 36: Zavegepant and the Gepant Class for Migraine Care

Author(s):

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Elyse Stock, MD, and Thomas Shiovitz, MD.

Episode 36 of the NeurologyLive Mind Moments podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.

The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.

Episode 36, "Zavegepant and the Gepant Class for Migraine Care," features interviews with Elyse Stock, MD, chief medical officer, Biohaven Pharmaceuticals, and Thomas Shiovitz, MD, director of California Neuroscience Research, to discuss the recently initiated phase 2/3 clinical trial of zavegepant, an oral CGRP-targeting agent for the prevention of migraine developed by Biohaven. The duo discusses how the investigational treatment fits into the gepant class and the impact that the gepants have had on migraine care overall.

EPISODE BREAKDOWN

1:40 – Stock on the background of this phase 2/3 clinical trial

4:15 – Shiovitz on zavegepant and its various formulations

5:25 – Stock on Biohaven's development of zavegepant

7:25 – Shiovitz on the gepant class in migraine

8:30 – Stock on the potential advantages of oral zavegepant

11:50 – Shiovitz on the takeaways for the clinical community

13:10 – Stock on Biohaven's goals in the migraine space

Click here to subscribe to the Mind Moments podcast. Be sure to leave a rating and review for the show. Thanks for listening!

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Subscribe Now!